VTRS Price Prediction Next Week
Analysis and Insights
News Impact:
Viatris Inc. (VTRS) has faced significant challenges recently, with its stock dropping 17.96% last week due to disappointing fourth-quarter earnings and lower-than-expected FY25 guidance. Analysts at B of A Securities have maintained an Underperform rating and reduced the price target from $11 to $10, reflecting diminished confidence in the stock's near-term performance.
Technical Analysis:
The stock is currently trading at $9.54, with key technical indicators suggesting bearish momentum:
- RSI (14): 33.01, indicating oversold conditions but not yet showing a bullish divergence.
- MACD: Negative crossover with a divergence below the signal line, signaling continued selling pressure.
- Fibonacci Levels: The stock is approaching the S1 support level of 9.05, with potential downside to 8.40 if this level is breached.
Fibonacci Pivot Analysis:
- Pivot Point: 10.11
- Resistance Levels: 11.16 (R1), 11.81 (R2)
- Support Levels: 9.05 (S1), 8.40 (S2)
Conclusion:
Given the bearish technical indicators and negative news sentiment, VTRS is expected to face continued downward pressure. The stock is likely to trade between 8.40 and 10.11 next week, with a potential target price of $9.20.
Recommendation: Sell or avoid buying VTRS in the next trading week due to the bearish technical setup and negative fundamental outlook.
VTRS Similar Chart Price Prediction
The price of VTRS is predicted to go up -1.73%, based on the high correlation periods with TFX. The similarity of these two price pattern on the periods is 98.2%.
VTRS
TFX
Down: -1.73%Similarity: 98.2%
VTRS Revenue Forecast
VTRS EPS Forecast
VTRS FAQs
What is VTRS revenue forecast for next quarter？
What is VTRS eps forecast for next quarter？
VTRS VS S&P500
A new focus on dermatology, ophthalmology, and gastroenterology will pave ways for many untapped opportunities that Viatris can utilize with its scale and manufacturing power.
Effective portfolio optimization and a promising pipeline of first-to-market launches will provide solid top line tailwinds.
Exiting biosimilars business will reallocate resources and help the company focus on long-term goals in its core generic and branded markets.
VTRS Analyst's Forecast
Glen Santangelo
Jefferies
Strong Buy
2025-03-07
Price Target
$15 → $13
Upside
+34.72%
Jefferies analyst Glen Santangelo lowered the firm's price target on Viatris to $13 from $15 and keeps a Buy rating on the shares after updating the firm's for Q4 results and 2025 guidance. While fundamentals continue to improve, with 3% organic growth expected in FY25, the company's negative headline EBITDA guidance has "overshadowed" improving operational performance, the analyst tells investors.
David Amsellem
Piper Sandler
Hold
2025-03-05
Price Target
$14 → $10
Upside
+5.49%
David Amsellem
Piper Sandler
Hold
2024-12-06
Price Target
$13 → $14
Upside
+10.06%
